A European Medicines Agency (EMA) committee recommended that Darzalex (daratumumab) given as an under-the-skin injection be approved for people…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
PANCREATIC CANCER
Atebimetinib shows potential for advanced pancreatic cancer: Trial
Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression…
Most people with hard-to-treat multiple myeloma who were given a combination treatment of Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) in…
Nearly 1 in 4 people with NPM1-mutated acute myeloid leukemia (AML) achieved complete remission after treatment with ziftomenib in a…
One-third of patients with hard-to-treat myeloma were alive and free from disease progression five years after a single infusion…
Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma,…
A U.S. Food and Drug Administration (FDA) committee has voted in favor of Darzalex Faspro (daratumumab and hyaluronidase-fihj) to…
BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been…
GYNECOLOGICAL CANCER
Pembrolizumab improves survival outcomes in ovarian cancer trial
Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among…
ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for…